EMVision Medical Devices Ltd (ASX:EMV)
Australia · Delayed Price · Currency is AUD | Market Cap | 155.24M -4.5% |
| Revenue (ttm) | 8.36M +57.2% |
| Net Income | -8.32M |
| EPS | -0.09 |
| Shares Out | 92.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,008 |
| Open | 1.680 |
| Previous Close | 1.725 |
| Day's Range | 1.640 - 1.705 |
| 52-Week Range | 1.470 - 2.430 |
| Beta | 1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About EMVision Medical Devices
EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia. [Read more]
Financial Performance
In fiscal year 2026, EMVision Medical Devices's revenue was 8.85 million, an increase of 75.17% compared to the previous year's 5.05 million. Losses were -8.32 million, -15.19% less than in 2025.
Financial StatementsNews
EMVision Medical Devices Annual report: H2 2026
EMVision Medical Devices has published its H2 2026 annual report on August 23, 2026.
EMVision Medical Devices Slides: H2 2026
EMVision Medical Devices has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 23, 2026.
EMVision Medical Devices Earnings release: Q3 2026
EMVision Medical Devices released its Q3 2026 earnings on April 12, 2026, summarizing the period's financial results.
EMVision Medical Devices Transcript: NWR Virtual Healthcare Conference
A novel portable brain scanner using radio frequency signals is advancing stroke and brain injury care, with strong clinical data, major partnerships, and a robust patent portfolio. Market entry is focused on hospitals and ambulances, with pivotal trials supporting regulatory submissions.
EMVision Medical Devices Transcript: Life Sciences Virtual Investor Forum
Portable brain scanners for stroke and traumatic brain injury are nearing pivotal trial completion, with strong clinical data and a U.S. launch targeted for 2027. The company is leveraging industry partnerships, robust IP, and a scalable business model to address large global markets.
EMVision Medical Devices Quarterly report: H1 2026
EMVision Medical Devices has published its H1 2026 quarterly earnings report on February 22, 2026.
EMVision Medical Devices Slides: H1 2026
EMVision Medical Devices has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 22, 2026.
EMVision Medical Devices Earnings release: Q2 2026
EMVision Medical Devices released its Q2 2026 earnings on January 27, 2026, summarizing the period's financial results.
EMVision Medical Devices Slides: FY 2025
EMVision Medical Devices has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 10, 2025.
EMVision Medical Devices Earnings release: Q1 2026
EMVision Medical Devices released its Q1 2026 earnings on October 27, 2025, summarizing the period's financial results.
EMVision Medical Devices Transcript: Investor Update
Transitioning to commercialization, two neurodiagnostic devices are advancing through pivotal clinical trials and regulatory pathways, targeting major U.S. and international markets. Strategic partnerships, robust funding, and a phased launch plan underpin growth, with multiple clinical and regulatory milestones ahead.
EMVision Medical Devices Slides: Investor Update
EMVision Medical Devices has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2025.